GlassScriptPhysician profile
Christopher H Kwoh
NPI 1962427534
$466,572.68
in general payments reported to CMS, 2019-2025
45 companies · $73K in 2025
The $73K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,258 · 2020: $11K · 2021: $80K · 2022: $87K · 2023: $67K · 2024: $143K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $236K · Travel and Lodging: $19K · Food and Beverage: $14K · Consulting Fee: $9,009 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,500 · Education: $32.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $235,728.50 |
| Travel and Lodging | $19,243.94 |
| Food and Beverage | $13,869.22 |
| Consulting Fee | $9,009.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,500.00 |
| Education | $32.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $249,241.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $178,198.22 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $18,104.34 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $4,672.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,760.75 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $2,304.36 | 2019-2025 | Vafseo, Auryxia |
| Csl Behring | $1,796.39 | 2024 | |
| Vifor Pharma, INC. | $1,099.66 | 2019-2025 | Veltassa |
| Nxstage Medical, INC. | $1,050.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $997.03 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $614.07 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $607.06 | 2021-2025 | |
| Amgen INC. | $604.63 | 2019-2025 | Krystexxa, Uplizna, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $593.47 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $486.31 | 2022-2025 | Tarpeyo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $449.94 | 2020-2025 | Benlysta |
| Opko Pharmaceuticals, LLC | $373.53 | 2019-2021 | |
| Ardelyx, INC. | $296.18 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $270.94 | 2023-2025 | Lupkynis |
| Novo Nordisk INC | $265.56 | 2024-2025 | Ozempic, Rybelsus, Rivfloza |
| Mallinckrodt Enterprises LLC | $226.38 | 2019 | |
| Ani Pharmaceuticals, INC. | $171.38 | 2022-2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $166.02 | 2021-2025 | Gattex |
| Lilly USA, LLC | $155.90 | 2022-2025 | Jardiance, Mounjaro |
| Shionogi INC | $141.31 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $134.34 | 2024-2025 | Voyxact |
| Mauna Kea Technologies, INC. | $88.53 | 2019 | |
| Daiichi Sankyo INC. | $79.55 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $74.96 | 2022-2025 | Oxlumo |
| Shire North American Group INC | $68.04 | 2019 | |
| Amarin Pharma, INC. | $62.75 | 2019-2020 | |
| Recor Medical INC | $49.65 | 2025 | Paradise Ultrasound Renal Denervation System |
| Apellis Pharmaceuticals, INC. | $48.20 | 2025 | Empaveli |
| Genzyme Corporation | $47.19 | 2022-2023 | |
| Kyowa Kirin, INC. | $46.70 | 2023-2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $40.79 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $39.85 | 2025 | Envarsus |
| Medtronic, INC. | $35.65 | 2023 | Ellipsys Vascular Access System |
| Genentech USA, INC. | $31.21 | 2025 | Gazyva |
| Ascendis Pharma Endocrinology INC | $29.23 | 2025 | Yorvipath |
| Scpharmaceuticals INC. | $17.41 | 2025 | |
| Boston Scientific Corporation | $15.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.51 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,208.07 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kwoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.